Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given an average recommendation of “Moderate Buy” by the nine research firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $62.25.

A number of equities analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. Citigroup assumed coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday.

Hedge Funds Weigh In On Celldex Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Arizona State Retirement System increased its holdings in Celldex Therapeutics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock worth $601,000 after buying an additional 325 shares in the last quarter. KBC Group NV increased its holdings in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 495 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 638 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 955 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 1,504 shares in the last quarter.

Celldex Therapeutics Stock Down 4.2 %

Shares of CLDX stock opened at $26.47 on Friday. The stock has a fifty day moving average of $33.90 and a 200 day moving average of $35.90. Celldex Therapeutics has a 52 week low of $24.43 and a 52 week high of $53.18. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -9.66 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The company had revenue of $3.19 million during the quarter, compared to analyst estimates of $1.44 million. Equities research analysts anticipate that Celldex Therapeutics will post -2.5 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.